

4th Annual Meeting of the Israeli Society for Cancer Research

The 2012 Cancer Route - From Bench to Bedside

8 May 2012

Wohl Center, Bar-Ilan University

14:30-15:30 POSTER SESSION

- P-1** CD84 IS A SURVIVAL RECEPTOR FOR CLL CELLS
Inbal Binsky-Ehrenreich¹, Ayelet Marom¹, Mirko Sobota, Frida Lantner¹, Michal Haran, Yair Herishanu², Idit Shachar¹
¹Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
²Department of Hematology, Sourasky Medical Center, Tel-Aviv, Israel
- P-2** TARGETING THE MUC1-SEA MODULE WITH ANTIBODIES FOR ABLATING HUMAN MUC1 POSITIVE CANCER CELLS AND CANCER STEM CELLS
Edward Pichinuk, Daniel Wreschner
Cell Research and Immunology, Tel-Aviv University, Tel-Aviv, Israel
- P-3** BLOOD GLUTAMATE SCAVENGERS PROLONG THE SURVIVAL OF RATS AND MICE WITH BRAIN-IMPLANTED GLIOMAS
Angela Ruban, Tamara Berkutzki, Itzik Cooper, Boaz Mohar, Vivian Teichberg
Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel
- P-4** LUNG AND COLON CANCER-SPECIFIC REGULATION OF ALTERNATIVE SPLICING
Dror Hollander¹, Moritz Aschoff², Schraga Schwartz³, Karl-Heinz Glatting², Roland Eils^{4,5}, Agnes Hotz-Wagenblatt², Rainer König^{4,5}, Gil Ast¹
¹Department of Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
²Bioinformatics "HUSAR", Genomics Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany
³Broad Institute, Harvard and MIT, Cambridge, USA
⁴Department of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁵Department of Bioinformatics and Functional Genomics, Institute of Pharmacy and Molecular Biotechnology, and Bioquant, University of Heidelberg, Heidelberg, Germany
- P-5** AS101 TREATMENT SENSITIZES ACUTE MYELOID LEUKEMIA CELLS (AML) TO CHEMOTHERAPY BY DISRUPTING THE INTERACTION BETWEEN VLA-4 INTEGRIN AND FIBRONECTIN:MECHANISMS OF ACTION AND CLINICAL APPLICATIONS
Adi Layani, Yona Kalechman, Benjamin Sredni
C.A.I.R. Institute, The Safdiè AIDS and Immunology Research Center, The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-6** EZH2 AND GATA3 PLAY OPPOSING ROLES IN CONTROLLING THE DIFFERENTIATION STATE OF BASAL-LIKE BREAST CANCER CELLS
Roy Granit¹, Tal Hadar¹, Yael Karamansha¹, Ithai Waldhorn¹, Irit Gat-Viks^{2,5}, Leah Liberman¹, Bella Maly³, Tamar Peretz⁴, Aviv Regev⁵, Ittai Ben-Porath¹
¹Department of Developmental Biology and Cancer Research, The Hebrew University of Jerusalem, Jerusalem, Israel
²Department of Immunology, Tel Aviv University, Tel-Aviv, Israel
³Department of Pathology, Hadassah Medical Center, Jerusalem, Israel
⁴Department of Oncology, Hadassah Medical Center, Jerusalem, Israel
⁵Department of Biology, Broad Institute of MIT and Harvard, Cambridge, USA

- P-7** FUNDAMENTAL CELL REGULATION BY ADAR1 ENZYME IS LOST IN METASTASIS BY microRNAs TO PROMOTE MALIGNANCY
Yael Wolff-Nemlich^{1,6}, Eyal Greenberg^{1,7}, Rona Ortenberg^{1,7}, Michal Besser^{1,7}, Iris Barshack², Jasmine Jacob-Hirsch³, Elad Jacoby^{3,4}, Victor Prieto⁸, Nitin Chakravarti⁸, Lyn Duncan¹⁰, David Kallenberg¹¹, Dorothy Bennett¹¹, Ninette Amariglio³, Menashe Bar-Eli⁹, Jacob Schachter¹, Gideon Rechavi^{3,6}, Gal Markel^{1,5,7}
¹*Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel*
²*Institute of Pathology, Sheba Medical Center, Ramat-Gan, Israel*
³*Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel*
⁴*Pediatric Hemato-oncology, Sheba Medical Center, Ramat-Gan, Israel*
⁵*Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel*
⁶*Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel*
⁷*Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel*
⁸*Pathology, MD Anderson Cancer Center, Houston, USA*
⁹*Cancer Biology, MD Anderson Cancer Center, Houston, USA*
¹⁰*Dermatopathology, 10Massachusetts General Hospital, Boston, USA*
¹¹*Biomedical Sciences Research Centre, St. George's, University of London, London, UK*
- P-8** LOW LEVELS OF MIR-151-5p AND MIR-451 PREDICT RELAPSE IN PEDIATRIC B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
Smadar Avigad^{1,3}, Jedan R.N. Verly^{1,2}, Gertjan J.L. Kaspers², Jacqueline Cloos², Anat Ohali^{1,3}, Michal Hameiri-Grossman^{1,3}, Keren Shichrur^{1,3}, Eva Fronkova⁴, Jan Trka⁴, Drorit Luria³, Yona Kodman³, Hadar Mirsky^{1,3}, Dafna Gaash^{1,3}, Marta Jeison³, Galia Avrahami³, Sara Elitzur³, Gil Gilad³, Batia Stark³, Isaac Yaniv^{1,3}
¹*Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel*
²*Pediatric Hematology Oncology, VU University Medical Center, Amsterdam, Netherlands*
³*Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel*
⁴*Department of Paediatric Haematology and Oncology, Charles University Prague, Prague, Czech Republic*
- P-9** MIR-192 DIRECTLY REGULATES DICER1 IN NEUROBLASTOMA, LEADING TO A MORE AGGRESSIVE DISEASE.
Galina Feinberg-Gorenshtein^{1,2}, Avital Guedj^{1,2}, Keren Shichrur^{1,2}, Marta Jeison³, Drorit Luria³, Shifra Ash^{2,3}, Meora Feinmesser^{2,4}, Liat Edry⁵, Noam Shomron⁵, Isaac Yaniv^{1,2,3}, **Smadar Avigad**^{1,2,3}
¹*Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel*
²*Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
³*Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Petah Tikva, Israel*
⁴*Institute of Pathology, Rabin Medical Center, Petah Tikva, Israel*
⁵*Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
- P-10** THE ROLE OF A-TO-I RNA EDITING ENZYME ADAR1 IN IMMUNE RESISTANCE OF MELANOMA CELLS
Gilli Galore Haskel^{1,2}, Yael Wolff-Nemlich^{1,2}, Mordechai Gutman³, Jacob Schachter², Gal Markel^{1,2,4}
¹*Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
²*Ella Institute of Melanoma, Sheba Medical Center, Tel Hashomer, Israel*
³*Department of General Surgery (Surgery B), Sheba Medical Center, Tel Hashomer, Israel*
⁴*Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel*
- P-11** ENGINEERING T CELLS TO IMPROVE HOMING CAPABILITIES TOWARDS HUMAN MELANOMA
Stav Kozlovski^{1,2}, Sivan Sapoznik¹, Michal Besser^{1,2}, Cyril Cohen³, Jacob Schachter¹, Gal Markel^{1,2,4}
¹*Ella Institute of Melanoma, Sheba Medical Center, Tel-Hashomer, Israel*
²*Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel*
³*Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel*
⁴*Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer, Israel*
- P-12** eIF4E TRANSLATION INITIATION FACTOR IS AN ATTRACTIVE THERAPEUTIC TARGET IN MULTIPLE MYELOMA
Oshrat Attar-Schneider^{1,3}, Liat Drucker^{1,3}, Victoria Zismanov^{1,3}, Shelly Tartakover Matalon^{1,3}, Michael Lishner^{1,2,3}
¹*Oncogenetic Laboratory, Meir Medical Center, Kfar-Saba, Israel*
²*Internal Medicine Department, Meir Medical Center, Kfar-Saba, Israel*
³*Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel*
- P-13** REDIRECTION OF T-CELLS FOR ADOPTIVE CELL TREATMENT OF CANCER IN A SPONTANEOUSLY PROGRESSING MAMMARY TUMOR MODEL
Anat Globerson, Tova Waks, Zelig Eshhar
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel

- P-14** CANCER ASSOCIATED FIBROBLASTS MEDIATE TUMOR-PROMOTING INFLAMMATION IN BREAST CANCER
Sarah Glanz¹, Charlotte Servais¹, Yael Raz¹, Camila Avivi², Iris Barshack², Neta Erez¹
¹*Department of Pathology, Tel-Aviv University, Tel-Aviv, Israel*
²*Department of Pathology, Sheba Medical Center, Tel-Hashomer, Israel*
- P-15** THYROID HORMONES ANTAGONIZE AND TETRAC, A DEAMINATED T4 ANALOG, SENSITIZES BORTEZOMIB ACTION IN MULTIPLE MYELOMA CELLS
Keren Cohen^{1,2}, Martin Ellis^{1,3}, Shafik Khoury¹, Paul J. Davis⁴, Aleck Herbergs⁵, Osnat Ashur-Fabian^{1,2}
¹*Translational Hemato-Oncology, Meir Medical Center, Kfar Saba, Israel*
²*Department of Human Molecular Genetics and Biochemistry, Tel-Aviv University, Tel-Aviv, Israel*
³*The Hematology Institute and Blood Bank, Meir Medical Center, Kfar Saba, Israel*
⁴*The Signal Transduction Laboratory, Ordway Research Institute, Albany, NY, USA*
⁵*Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA*
- P-16** HOST RESPONSE TO LOCAL RADIOTHERAPY MAY ENHANCE METASTATIC SPREAD IN MICE
Rotem Bril¹, Orit Kaidar-Person², Mark Shilkrut², Svetlana Gingis-Velitzki¹, Valeria Miller¹, Rahamim Ben-Yosef², Abraham Kuten², Yuval Shaked¹
¹*Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel*
²*Oncology, Rambam Health Care Campus, Haifa, Israel*
- P-17** VEGF-C SECRETED BY MACROPHAGES IN RESPONSE TO PACLITAXEL THERAPY MAY ACCOUNT FOR CHEMOTHERAPY-ENHANCED METASTASES IN MICE
Svetlana Gingis-Velitzki¹, Dov Hershkovitz³, Orit Kaidar-Person², Inna Naroditsky³, Rotem Bril¹, Ella Fremder¹, Abraham Kuten², Yuval Shaked¹
¹*Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Haifa*
²*Department of Oncology, Rambam Health Care Campus, Haifa, Israel*
³*Department of Pathology, Rambam Health Care Campus, Haifa, Israel*
- P-18** MAMMARY FIBROBLASTS ARE ACTIVATED TO BECOME PRO-INFLAMMATORY BY BREAST TUMOR CELLS
Yoray Sharon, Lina Alon, Yael Raz, Neta Erez
Department of Pathology, Tel-Aviv University, Tel-Aviv, Israel
- P-19** AMINO ACID STARVATION SENSITIZES CANCER CELLS TO PROTEASOME INHIBITION
Noam Cohen, Sarit Mizrachy-Schwartz, Shoshana Klein, Nataly Kravchenko-Balasha, Alexander Levitzki
Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel
- P-20** TARGETING INSULIN RECEPTOR SUBSTRATES FOR DESTRUCTION AS A THERAPEUTIC MODALITY FOR CANCERS
Efrat Flashner¹, Hadas Reuveni², Lilach Steiner¹, Kirill Makedonski^{1,2}, Alexei Shir^{1,2}, Alexander Levitzki¹
¹*Biological Chemistry, The Hebrew University, Jerusalem, Israel*
²*NovoTyr Therapeutics, Tel Hai, Israel*
- P-21** E6 TOGETHER WITH E6AP UPREGULATE THE LEVELS OF β -CATENIN INDEPENDENT OF THE E6AP UBIQUITIN LIGASE ACTIVITY
Sophia Sominsky, **Yael Kuslansky**, Anna Jackman, Levana Sherman
Human Microbiology, Sacler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- P-22** IMPAIRED ANGIOGENESIS MEDIATES DORMANCY OF HUMAN GLIOBLASTOMA-DERIVED CLONE: CROSSTALK BETWEEN POOR ANGIOGENIC POTENTIAL AND PROLONGED TUMOR DORMANCY
Shiran Ferber¹, Ehud Segal¹, Nava Almog², Ronit Satchi-Fainaro¹
¹*Physiology and Pharmacology, Tel-Aviv University, Tel-Aviv, Israel*
²*Center of Cancer Systems Biology, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, USA*
- P-23** PACLITAXEL RESISTANCE CORRELATES WITH $\alpha_v\beta_3$ INTEGRIN EXPRESSION AND OVERCOMED WITH RGD-BEARING NANOCONJUGATE
Anat Eldar-Boock¹, Joaquin Sanchis², Ruth Lupu³, María J. Vicent², Ronit Satchi-Fainaro¹
¹*Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
²*Medicinal Chemistry Unit, Polymer Therapeutics Laboratory, Centro de Investigación Príncipe Felipe, Valencia, Spain*
³*Mayo Medical Laboratories, Mayo Clinic, Rochester, USA*

- P-24 TUMOR-TARGETED DELIVERY OF SIRNA AS A DUAL ANTICANCER AND ANTI-ANGIOGENIC THERAPY**
Paula Ofek¹, Wiebke Fischer², Marcelo Calderon², Fatemeh Sheikhi-Mehrabadi², Rainer Haag², Ronit Satchi-Fainaro¹
¹*Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel*
²*Organic Chemistry, Freie University, Berlin, Germany*
- P-25 BRAF MUTATIONS, USE OF BEVACIZUMAB AND SURVIVAL OF COLORECTAL CANCER**
Katerina Shulman^{1,2}, Ofra Barnett-Griness¹, Meira Frank¹, Abraham Kuten², Stephen B. Gruber³, Flavio Lejbkowitz¹, Gad Rennert¹
¹*CHS National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel*
²*Oncology Department, Rambam Health Care Campus, Haifa, Israel*
³*Keck School of Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, USA*
- P-26 AS101 PROTECTS AGAINST CHEMOTHERAPY-INDUCED FOLLICLE ACTIVATION AND INFERTILITY. A NOVEL SAFE APPROACH FOR FERTILITY PRESERVATION IN CANCER PATIENTS**
Lital Kalich-Philosoph^{1,2}, Hadassa Roness², Alon Carmely^{1,2}, Hagai Ligumsky^{3,4}, Ido Wolf^{3,4}, Dror Meirou^{2,4}, Benjamin Sredni¹
¹*The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel*
²*Department of Obstetrics and Gynecology, Fertility Preservation Research Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel*
³*Cancer Research Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel*
⁴*Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel*
- P-27 MiCRORNA125a-3p INHIBITS FYN-MEDIATED ONCOGENIC PATHWAY IN PROSTATE CANCER CELLS**
Lihi Ninio-Many¹, Hadas Grossman¹, Irit Ben-Aharon², Salomon M. Stemmer², Noam Shomron¹, Ruth Shalgi¹
¹*Department of Cell and Developmental Biology, Tel-Aviv University, Sackler Faculty of Medicine, Israel*
²*Davidoff Center, Institute of Oncology, Belinson Campus, Rabin Medical Center, Tel-Aviv University, Petach-Tikva, Israel*
- P-28 TUMOR CELL iNOS REGULATION BY miR-146a: TRANSLATIONAL INHIBITION AS MEANS TO ESCAPE MACROPHAGE-INDUCED DEATH**
Miki Rahat, Miriam Walter, Nitza Lahat
Immunology, Carmel Medical Center and The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
- P-29 THE DIFFERENTIAL EFFECT OF ANTI-VEGF THERAPY IN MACROSCOPIC VERSUS MICROSCOPIC TUMORS MA DEPEND ON BMDC COLONIZATION OF TREATED TUMOR SITE**
Dror Alishekevitz¹, Rotem Brill¹, Valeria Miller¹, Tali Voloshin¹, Svetlana Gingis-Velitski¹, Ella Fremder¹, Michal Munster¹, Stefan J. Scherer², Yuval Shaked¹
¹*Molecular Pharmacology, Technion, Haifa, Israel*
²*Department of Oncology, Hoffmann La Roche, Basel, Switzerland*
- P-30 MALIGNANT OVARIAN ASCITES FLUID DERIVED CANCER CELL SUBPOPULATIONS PRESENT MARKERS CHARACTERISTIC OF CANCER STEM CELLS**
Roni Shouval, Karl Skorecki, Maty Tzukerman
Molecular Medicine Laboratory, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- P-31 MR AND HEMODYNAMIC RESPONSE IMAGING (HRI) FOR MONITORING THE EFFICACY OF A NOVEL ANTI-ANGIOGENESIS DRUG COMBINATION ON A NEUROBLASTOMA MOUSE MODEL**
Chani Komar^{1,2}, Eitan Gross³, Elia Dery^{1,2}, Nathalie Corchia^{1,2}, Keren Meir⁴, Muli Ben-Sasson⁵, Rinat Abramovitch^{1,2}
¹*The Goldyne Savad Institute for Gene Therapy, Hadassah Hebrew University Medical School, Jerusalem, Israel*
²*MRI/MRS lab HBRC, Hadassah Hebrew University Medical School, Jerusalem, Israel*
³*Pediatric Surgery, Hadassah Hebrew University Medical School, Jerusalem, Israel*
⁴*Pathology, Hadassah Hebrew University Medical School, Jerusalem, Israel*
⁵*Developmental Biology and Cancer Research, Hadassah Hebrew University Medical School, Jerusalem, Israel*
- P-32 THE LATS2 TUMOR SUPPRESSOR AUGMENTS p53-MEDIATED APOPTOSIS**
Yael Aylon¹, Norikazu Yabuta², Eleonora Lapi³, Hiroshi Nojima², Xin Lu³, Moshe Oren¹
¹*Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel*
²*Department of Molecular Genetics, Osaka University, Osaka, Japan*
³*Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK*

- P-33** ENHANCEMENT OF LYMPHOCYTE ANTI-TUMOR ACTIVITY USING CO STIMULATORY CHIMERIC RECEPTORS
Chen Ankri, Miri Fried, Cyrille J. Cohen
The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-34** MIRNA-MEDIATED TUMOR DORMANCY – THE ROLE OF MIR93 AND MIR200C IN THE ANGIOGENIC SWITCH
Galia Tiram¹, Ehud Segal¹, Gal Bachar¹, Roni Shreberk¹, Paula Ofek¹, Taturu Udagawa², Liat Edry³, Noam Shomron³, Ronit Satchi-Fainaro¹
¹*Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
²*Vascular Biology Program and Department of Surgery, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts, USA*
³*Cell & Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel*
- P-35** MECHANISMS LINKING ALTERED METABOLISM TO OBESITY-RELATED COLON CANCER
Einav Yehuda-Shnaidman¹, Lili Nimri¹, Assaf Rudich², Betty Schwartz¹
¹*School of Nutritional Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel*
²*Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University, Beer Sheva, Israel*
- P-36** MUTANT p53 PROLONGS NF-kappaB ACTIVATION AND PROMOTES COLITIS AND COLORECTAL TUMORIGENESIS
Tomer Cooks¹, Ioannis Pateras², Ohad Tarcic¹, Hilla Solomon¹, Eli Pikarski⁴, Giulermina Lozano³, Varda Rotter¹, Vassilis Gorgoulis², Moshe Oren¹
¹*Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel*
²*School of Medicine, University of Athens, Athens, Greece*
³*Department of Genetics, MD Anderson, Texas, USA*
⁴*Dept. of Immunology & Cancer Research, Hadassah Medical School, Jerusalem, Israel*
- P-37** A SWITCH IN S6K1 ALTERNATIVE SPLICING MODULATES mTORC1 ACTIVITY
Vered Ben-Hur, Rotem karni
Biochemistry and Molecular Biology, Hebrew University-Hadassah Medical School, Jerusalem, Israel
- P-38** FISHING FOR NEW BREAST AND OVARIAN CANCER GENES
Carmit Strauss, Michal Goldberg
The Genetics Department, The Hebrew University, Jerusalem, Israel
- P-39** RBM38 IS A DIRECT TRANSCRIPTIONAL TARGET OF E2F1 THAT LIMITS E2F-INDUCED PROLIFERATION
Orit Feldstein, Doron Ginsberg
The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-40** THE LONG NON-CODING RNA ANRIL IS A DIRECT TRANSCRIPTIONAL TARGET OF E2F1 THAT MEDIATES E2F1-INDUCED PROLIFERATION
Dana Bashari, Adi Jerbi, Orit Feldstein, Doron Ginsberg
The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-41** TARGETING OF TUMORS BY T-LYMPHOCYTES ENGINEERED TO EXPRESS NK RECEPTORS
Shlomo Yaacobi¹, Yair Tal¹, Miryam Horovitz-Fried¹, Angel Porgador², Cyrille J. Cohen¹
¹*The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel*
²*Faculty of Health Sciences, Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beer-Sheva, Israel*
- P-42** INDUCTION OF ANTI-TUMOR IMMUNITY AGAINST MOUSE COLON CARCINOMA TUMORS FOLLOWING TUMOR ABLATION BY INTRATUMORAL ²²⁴Ra-LOADED WIRES
Hila Confino¹, Ilan Hochman¹, Margalit Efrati¹, Michael Schmidt², Gideon Halperin¹, Itzhak Kelson², Yona Keisari¹
¹*Microbiology and Clinical Immunology, Tel Aviv University - Sackler Faculty of Medicine, Tel Aviv, Israel*
²*School of Physics and Astronomy, Tel Aviv University - Sackler Faculty of Exact sciences, Tel Aviv, Israel*

- P-43** A PHENANTHRENE DERIVED PARP INHIBITOR EXCLUSIVELY ERADICATES HUMAN CANCER CELLS BY 'MITOTIC CATASTROPHE' CELL DEATH
Malka Cohen-Armon¹, Asher Castiel², Leonid Visochek³, Shai Izraeli⁴, Françoise Dantzer⁵
¹*Physiol & Pharmacol and the Neufeld Cardiac Research Institute, Tel-Aviv University, Tel-Aviv, Israel*
²*Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel*
³*Neufeld Cardiac Research Institute, Tel-Aviv University, Tel-Aviv, Israel*
⁴*Department of Human Molecular Genetics and Biochemistry and Cancer Research Center, Tel-Aviv University and Sheba Medical Center, Tel-Aviv and Ramat Gan, Israel*
⁵*Biotechnology and Cell Signaling, Ecole Supérieure de Biotechnologie Strasbourg, Strasbourg, France*
- P-44** FOLATED DRUG DELIVERY SYSTEMS OF DOXORUBICIN FOR THE TREATMENT OF CANCER
Anna Scomparin¹, Anat Eldar-Boock¹, Shiran Ferber¹, Galia Tiram¹, Hilary Shmeeda², Alberto Gabizon², Stefano Salmaso³, Paolo Caliceti³, Ronit Satchi-Fainaro¹
¹*Department of Physiology and Pharmacology, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel*
²*Department of Oncology, Shaare Zedek Medical Center and Hebrew University-School of Medicine, Jerusalem, Israel*
³*Department of Pharmaceutical Sciences, University of Padova, Padova, Italy*
- P-45** p53, A NOVEL REGULATOR OF LIPID METABOLISM PATHWAYS
Ido Goldstein, Osnat Ezra, Noa Rivlin, Alina Molchadsky, Shalom Madar, Naomi Goldfinger, Varda Rotter
Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
- P-46** METABOLIC PHENOTYPIC ANALYSIS UNCOVERS REDUCED PROLIFERATION IN LATE STAGE BREAST CANCER
Livnat Jerby¹, Lior Wolf¹, Carsten Denkert², Gideon Y Stein^{3,4}, Mika Hilvo⁵, Matej Oresic⁵, Tamar Geiger³, Eytan Ruppin^{1,3}
¹*The Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel*
²*Institute of Pathology, Charité Hospital, Berlin, Germany*
³*The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
⁴*Department of Internal Medicine 'B', Beilinson Hospital, Rabin Medical Center Israel, Petah-Tikva, Israel*
⁵*VTT, Technical Research Centre of Finland, Espoo, Finland*
- P-47** PSYCHOLOGICAL RISK FACTORS FOR COLORECTAL CANCER?
Shulamith Kreitler¹, Michal M. Kreitler², Asaf Len³, Frida Barak⁴
¹*Psychology and Psychooncology Research Center, Tel-Aviv University and Sheba Medical Center, Tel-Aviv, Israel*
²*Psychology, Tel-Aviv University, Tel-Aviv, Israel*
³*Ear, Nose and Throat, Wolfson Hospital, Holon, Israel*
⁴*Oncology Department, Barzilai Medical Center, Ashkelon, Israel*
- P-48** FUNCTIONAL GENOMICS UNRAVEL THE ROLE OF ERG IN THE DEVELOPMENT OF ACUTE MYELOID LEUKEMIA AND IDENTIFIES THERAPEUTIC TARGETS
Liat Goldberg^{1,4}, Yehudit Birger¹, Marloes Tijssen², Rebecca Hanna², Berthold Gottgens², Jasmine Jaccob-Hirsch¹, Anat Taragan³, Yoel Kloog³, Shai Izraeli^{1,4}
¹*Functional Genomics and childhood leukemia research, Sheba Medical Center, Ramat-Gan, Israel*
²*Department of Haematology, University of Cambridge, Cambridge institute for Medical Research, Cambridge, UK*
³*Neurobiology, Tel-Aviv University, Tel-Aviv, Israel*
⁴*Human Molecular Genetics and Biochemistry, Tel-Aviv University, Tel-Aviv, Israel*
- P-49** SILENCING OF A LARGE micro-RNA CLUSTER ON HUMAN CHROMOSOME 14q32 IN MELANOMA: BIOLOGICAL EFFECTS OF mir-376a and mir-376c ON INSULIN GROWTH FACTOR 1 RECEPTOR
Liron Zehavi^{1,2}, Raya Leibowitz-Amit^{3,2}, Dror Avni², Yehezkel Sidi^{1,2}
¹*Department of Molecular Genetics and Clinical Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
²*Cancer Research Center and Department of Medicine C, Sheba Medical Center, Tel Hashomer, Israel*
³*Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel*
- P-50** A CROSS-TALK BETWEEN p53 AND Ras IN THE MALIGNANT PROCESS
Hilla Solomon¹, Yosef Buganim¹, Leslie Pomeranic¹, Tsevi Beatus², Yael Assia¹, Ira Kogan-Sakin¹, Shalom Madar¹, Ido Goldstein¹, Ran Brosh¹, Eyal Kalo¹, Naomi Goldfinger¹, Varda Rotter¹
¹*Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel*
²*Department of Materials and Interfaces, Weizmann Institute of Science, Rehovot, Israel*
- P-51** CARBOXYPEPTIDASE E (CPE) - A NEGATIVE REGULATOR OF THE CANONICAL Wnt SIGNALING PATHWAY
Nir Skalka, Michal Caspi, Rina Rosin-Arbesfeld
Anatomy and Anthropology, Tel-Aviv University, Tel-Aviv, Israel

- P-52** COMPARING TÊTE-À-TÊTE LINEAR AND SPHERICAL POLYMERIC ARCHITECTURES FOR TARGETED DELIVERY OF DOXORUBICIN
Dina Polyak¹, Claudia Ryppa², Felix Kratz², Boris Polyak³, Ronit Satchi-Fainaro¹
¹*Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel*
²*Division of Macromolecular Prodrugs, Tumor Biology Center, Freiburg, Germany*
³*Department of Surgery, Drexel University College of Medicine, Philadelphia, USA*
- P-53** TUMOR ASSOCIATED NEUTROPHIL (TAN) DEVELOP PRO-TUMORIGENIC PROPERTIES DURING TUMOR PROGRESSION
Inbal Mishalian, Bayuch Rachel, Zolotriob Lida, Levy Liran, Fridlender Zvi
Inst. of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- P-54** THE INFLUENCE OF P53 MUTATIONS ON ITS PRESENTATION BY THE MHC SYSTEM
Katrina Shamalov
The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel, Israel
- P-55** FIBROBLAST GROWTH FACTOR RECEPTORS IN MELANOMA: POTENTIAL TARGETS FOR INHIBITION OF TUMOR GROWTH AND METASTASIS?
Michael Grusch^{1,2}, Sivan Izraely², Karin Schelch¹, Shlomit Ben-Menahem², Maayan Tahor², Anat Klein², Petra Heffeter¹, Christine Pirker¹, Orit Sagi-Assif², Walter Berger¹, Isaac P. Witz²
¹*Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Vienna, Austria*
²*Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel*
- P-56** THE CYTOKINE MIDKINE AND ITS RECEPTOR RPTPz REGULATE B CELL SURVIVAL IN A PATHWAY INDUCED BY CD74
Sivan Cohen¹, Or-yam Shoshana¹, Einat Zelman-Toister¹, Nitsan Maharshak¹, Inbal Binsky-Ehrenreich¹, Maya Gordin¹, Lev Shvidel², Michal Haran², Lin Leng³, Richard Bucala³, Sheila Harroch⁴, Idit Shachar¹
¹*Immunology, The weizmann institute of science, Rehovot, Israel*
²*Hematology, Hematology Institute, Kaplan Medical Center, Rehovot, Israel*
³*Medicine, University School of Medicine, New Haven, USA*
⁴*Neuroscience, Institut Pasteur, Paris, France*
- P-57** $\gamma\delta$ T CELLS FOR ADOPTIVE IMMUNOTHERAPY OF GLIOBLASTOMA MULTIFORME
Victoria Marcu¹, Naama Peshes-Yaloz², Zvi Cohen², Ilan Bank¹
¹*Laboratory for Immunoregulation, Chaim Sheba Medical Center, Tel Hashomer, Israel*
²*Neurosurgery research Laboratory, Chaim Sheba Medical Center, Tel Hashomer, Israel*
- P-58** DOWNREGULATION OF MIR-31, MIR-155, AND MIR-564 IN CHRONIC MYELOID LEUKEMIA CELLS
Oshrat Hershkovitz-Rokah¹, Galit Granot¹, Adelina Ovcharenko¹, Shira Modai², Metsada Pasmanik-Chor³, Amos Toren⁴, Noam Shomron², Ofer Shpilberg^{1,5}
¹*Department of Hematology, Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel*
²*Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
³*Bioinformatics Unit, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
⁴*Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Tel-Hashomer, Ramat Gan, Israel*
⁵*Department of Hematology, Institute of Hematology, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah Tikva, Israel*
- P-59** CANCER and DEVELOPMENT: PERTURBATION OF FETAL HEMATOPOIESIS IN A MOUSE MODEL OF DOWN SYNDROME TRANSIENT MYELOPROLIFERATIVE DISORDER
Yehudit Birger¹, Liat Goldberg¹, Inna Muler¹, Jasmin Jacob-Hirsch¹, Shai Izraeli²
¹*Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel*
²*Cancer Research Center and Human Molecular Genetics and Biochemistry, Sheba Medical Center and Tel Aviv University, Tel Hashomer, Israel*
- P-60** CURE OF PRIMARY TUMORS BY ELECTRIC BASED-ABLATION CAN STIMULATE ANTI TUMOR IMMUNITY
Ilan Hochman^{1,2}, Hila Confino¹, Margalit Efrati¹, Rafi Korenstein², Yona Keisari¹
¹*Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv, Israel*
²*Departments of Physiology & Pharmacology, Sackler Faculty of Medicine, Tel Aviv, Israel*

- P-61 CHARACTERIZATION OF KLOTHO FUNCTION-STRUCTURE RELATIONSHIP**
Keren Merenbakh^{1,2}, Hagai Ligumsky^{1,2}, Shiri Shahmoon^{1,2}, Tami Rubinek¹, Ido Wolf^{1,2}
¹Sheba Medical Center, Institute of Oncology, Ramat-Gan, Israel
²Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
- P-62 DIFFERENTIAL EFFECTS OF KLOTHO ON OXIDATIVE STRESS IN NORMAL AND BREAST CANCER CELLS**
Irina Lojkin^{1,2}, Tami Rubinek¹, Ido Wolf^{1,2}
¹Institute of Oncology, Sheba Medical Center, Ramat Gan, Israel
²Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- P-63 AN HCC GENOMIC AMPLIFICATION REGULATES THE TUMOR MICROENVIRONMENT AND MARKS TUMORS SENSITIVE FOR VEGF-A INHIBITION**
Elad Horwitz¹, Ilan Stein^{1,3}, Julia Nemeth², Avivit Shoham¹, Orit Pappo³, Naama Kanarek¹, Farid Zreik^{1,3}, Rinnat Porat^{1,3}, Hendrik Reuter², Jochen Hess², Kai Breuhahn², Peter Angel², Yinon Ben-Neriah¹, Eli Pikarsky^{1,3}
¹The Lautenberg Center for Immunology, The Hebrew University, Jerusalem, Israel
²Division of Signal Transduction and Growth Control (A100), German Cancer Research Center (DKFZ), Heidelberg, Germany
³Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- P-64 RTVP-1 IS ASSOCIATED WITH THE MESENCHYMAL DIFFERENTIATION OF GLIOMA AND GLIOMA STEM CELLS (GSCs) AND PROMOTES THEIR SELF-RENEWAL**
Nissim Giladi¹, Amotz Ziv-Av¹, Hae Kyung Lee², Susan Finniss², Simona Cazacu², Cunli Xiang², Laila Poisson², Tom Mikkelsen², Chaya Brodie^{1,2}
¹The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
²Hermelin Brain Tumor Center, Dept. of Neurosurgery, Henry Ford Hospital, Detroit, USA
- P-65 REGULATION OF GLIOMA CELL MIGRATION AND INVASION BY RTVP-1**
Nissim Giladi¹, Amotz Ziv-Av¹, Hae-Kyung Lee², Simona Cazacu², Susan Finniss², Cunli Xiang², Chaya Brodie^{1,2}
¹The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
²Hermelin Brain Tumor Center, Dept. of Neurosurgery, Henry Ford Hospital, Detroit, USA
- P-66 KLOTHO-INDUCED DISSOCIATION BETWEEN ACTIVATION AND NUCLEAR LOCALIZATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE (ERK) 1/2: A NOVEL GROWTH INHIBITORY MECHANISM IN BREAST CANCER**
Shiri Shahmoon^{1,2}, Tami Rubinek¹, Rony Seger³, Ido Wolf^{1,2}
¹Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
²Department of Oncology, Sackler Faculty of Medicine, Tel-Aviv, Israel
³Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel
- P-67 KLOTHO, A NOVEL REGULATOR OF SOMATOTROPE PROLIFERATION AND HORMONE SECRETION**
Shiri Shahmoon^{1,3}, Hadara Rubinfeld², Ido Wolf^{1,3}, Tami Rubinek¹
¹Institute of Oncology, Sheba Medical Center, Ramat-Gan, Israel
²Felsenstein Research Center, Rabin Medical Center, Petah Tikva
³Department of Oncology, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel
- P-68 NEW VIEWS ON MICRORNAS INVOLVEMENT IN MELANOMA**
Eyal Greenberg^{1,2}, Eran Eyal³, Liat Hershkovitz¹, Yael Nemlich¹, Steven Hajdu¹, Orit Itzhaki¹, Liat Edry⁴, Oz Solomon^{3,5}, Ninette Amariglio³, Michal Besser¹, Yona Keisari², Gideon Rechavi^{3,7}, Noam Shomron⁴, Jacob Schachter¹, Gal Markel^{1,2,6}
¹Ella Institute of Melanoma, Sheba Medical Center, Ramat-Gan, Israel
²Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
³Cancer Research Center, Sheba Medical Center, Ramat-Gan, Israel
⁴Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁵Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel
⁶Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel
⁷Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- P-69 TOWARDS RESTORING FOLDING AND FUNCTION OF MUTANT P53 IN VIVO**
Gal Herzog, Liel Aillenber, Merav Shmueli, Michaela Yanku, Meital Asher, Michal Levy, Ehud Gazit, Daniel Segal
The Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel

- P-70** ADAR1 and ADAR3 EXPRESSION IS DECREASED IN GLIOBLASTOMA AND THEY REGULATE GLIOMA CELL MIGRATION AND RESPONSE TO RADIO- AND CHEMO-THERAPY
Anna Dubnik¹, Susan Finnis², Cunli Xiang², Simona Cazacu², Ninette Amariglio³, Gideon Rechavi³, Chaya Brodie¹
¹The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan
²Hermelin Brain Tumor Center Dept. of Neurosurgery, Henry Ford Hospital, Detroit, USA
³Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel
- P-71** 4-1BB TRANSDUCED HUMAN T CELLS DEMONSTRATE AN IMPROVED ANTI-TUMOR ACTIVITY
Inbal Daniel-Meshulam, Cyril Cohen
Life Science, Bar-Ilan University, Ramat-Gan, Israel
- P-72** GRANULE EXOCYTOSIS MEDIATES IMMUNE SURVEILLANCE OF SENESCENT CELLS
Adi Sagiv¹, Anat Biran¹, Scott W. Lowe², Valery Krizhanovsky¹
¹Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
²Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, USA
- P-73** BIOMARKER ROBUSTNESS REVEALS THE PDGF NETWORK AS DRIVING DISEASE OUTCOME IN OVARIAN CANCER PATIENTS IN MULTIPLE STUDIES
Rotem Ben-Hamo, Sol Efroni
The Mina and Everard Goodman Faculty of Life Science, Bar-Ilan University, Ramat-Gan, Israel
- P-74** GENE EXPRESSION AND NETWORK-BASED ANALYSIS REVEALS A NOVEL ROLE FOR hsa-miR-9 AND DRUG CONTROL OVER THE p38 NETWORK IN GLIOBLASTOMA MULTIFORME PROGRESSION /h1
Rotem Ben-Hamo, Sol Efroni
The Mina and Everard Goodman Faculty of Life Science, Bar-Ilan University, Ramat-Gan, Israel
- P-75** THE EFFECT OF FORCHLORFENURON ON HIF-1a PROTEIN IN CANCER CELLS
Dikla Vardi-Oknin, Maya Golan, Nicola Mabjeesh
Prostate Cancer Research Laboratory, Department of Urology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv, Israel
- P-76** GATA3 REGULATES CELLULAR PHENOTYPES IN BREAST CANCER
Ilana Brutman, Helit Cohen, Sol Efroni
The Mina and Everard Goodman Faculty of Life Science, Bar-Ilan University, Ramat-Gan, Israel
- P-77** STIL, A PROTEIN OVEREXPRESSED IN MULTIPLE CANCERS, IS REQUIRED FOR CENTRIOLE DUPLICATION AND PRIMARY CILIA ORGANELLE FORMATION IN MAMMALIAN CELLS
Ahuvit David^{1,2}, Julia Vulprecht³, Asher Castiel^{1,2}, Alwin Krämer³, Shai Izraeli^{1,2}
¹Sheba Cancer Research Center and the Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel
²Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
³Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Dept. of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
- P-78** FROM SPERMATOGENESIS TO CANCER CELLS: THE MITOCHONDRIAL FER T/FER LINK
Ariela Segal, Etai Yaffe, Elad Hikri, Adar Makovski, Sally Shpungin, Uri Nir
The Mina and Everard Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-79** HIF-1a and β -TrCP INTERACTIONS IN CANCER CELLS
Maya Cohen, Maya Golan, Nicola Mabjeesh
Urology, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel
- P-80** ENHANCING THE ANTI-TUMOR ACTIVITY OF T CELLS BY IMPROVING THE EXPRESSION OF THE TCR CHAINS USING DIFFERENT LEADER SEQUENCES
Viki Raz Djanashvili, Miryam Horovitz-Fried, Cyrille J. Cohen
The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-81** SECOND GENERATION TYROSINE KINASE INHIBITORS REDUCE TELOMERASE ACTIVITY IN K562 CELLS
Saar Shapira¹, Rahav Mor-Tzuntz¹, Galit Granot¹, Pia Raanani^{1,2}, Orit Uziel¹, Meir Lahav^{1,3}, Ofer Shpilberg^{1,2}
¹Sackler School of Medicine, Felsenstein Medical Research Center, Belinson Hospital, Tel Aviv University, Israel
²Sackler School of Medicine, Institute of Hematology, Davidoff Cancer Center, Belinson Hospital, Tel Aviv University, Israel
³Sackler School of Medicine, Medicine A, Belinson Hospital, Tel Aviv University, Israel

- P-82** SPLENECTOMY INHIBITS TUMOR DEVELOPMENT AND METASTASES IN MURINE LUNG CANCER MODELS
Liran Levy, Inbal Mishalian, Lida Zolotarob, Rachel Bayuh, Zvi Fridlender
Inst. of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
- P-83** A POSSIBLE ROLE FOR PHOX2B IN THE SWITCH FROM MICRO TO MACRO METASTASIS IN NEUROBLASTOMA
Maayan Tahor, Shelly Maman, Tsipi Meshel, Ilana Yron, Isaac P. Witz, Orit Sagi-Assif
Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel
- P-84** CLASSIFYING DISEASE EXPRESSION PROFILES USING NETWORKS
 Ofer Lavi¹, **David Amar**¹, Gideon Dror², Ron Shamir¹
¹*Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel*
²*Department of Computer Science, Tel Aviv College, Tel Aviv, Israel*
- P-85** IDENTIFYING SPLICING TARGETS OF THE SPLICING FACTOR HNRNP A2/B1 IN BREAST CANCER USING NEXT GENERATION RNA SEQUENCING
Ilana Loinger-Lebenthal¹, Regina Golan-Gerstl¹, Jasmine Jacob-Hirsch², Karen Cesarkas², Gideon Rechavi², Rotem Karni¹
¹*The Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Department of Biochemistry and Molecular Biology, Jerusalem, Israel*
²*Cancer Research Center, Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel*
- P-86** ENHANCED ADHESION AND MIGRATION AND INDUCTION OF Pyk2 complex FORMATION IN NB4 CELLS FOLLOWING ATRA TREATMENT
Adelina Ovcharenko¹, Galit Granot¹, Ofer Shpilberg², Pia Raanani²
¹*Hematology, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Petah Tiqva, Israel*
²*Hematology, Institute of Hematology, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Petah Tiqva, Israel*
- P-87** INTRATUMORAL ALPHA RADIATION EFFECTIVELY ABLATED TRANSPLANTED MURINE BREAST TUMORS AND RELEASED ANTIGENS WHICH TRIGGERED PROTECTIVE ANTI-TUMOR IMMUNITY
Margalit Efrati¹, Hila Confino¹, Ilan Hochman¹, Michael Schmidt², Itzhak Kelson², Yona Keisari¹
¹*Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
²*School of Physics and Astronomy, Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, Israel*
- P-88** RNF20 AS A POSSIBLE MOLECULAR LINK BETWEEN INFLAMMATION AND CANCER
Ohad Tarcic, Tomer Cooks, Moshe Oren
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
- P-89** THE AFFECT OF TUMOR-SUPPRESSOR LOSS ON REPLICATION DYNAMICS IN EARLY STAGES OF TUMORIGENESIS
Maayan Roniger, Assaf C. Bester, Batsheva Kerem
Department of Genetics, The Hebrew University, Jerusalem, Israel
- P-90** EXPLOITING BRIGHT FIELD MICROSCOPY TO QUANTIFY COLLECTIVE CELLS MIGRATION
Assaf Zaritsky¹, Sari Natan², Eshel Ben-Jacob³, Ilan Tsarfaty²
¹*Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel*
²*Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel*
³*School of Physics and Astronomy, Tel Aviv University, Tel Aviv, Israel*
- P-91** EXPOSURE TO LIGHT AT NIGHT AND ITS ASSOCIATION WITH BREAST CANCER - CAN WE THINK ON WAYS OF PREVENTION?
Atalya Keshet - Sitton, Abraham Haim
The Israeli Center for interdisciplinary Research in Chronobiology and The Department of Natural Resources & Environmental Management, Haifa University, Haifa, Israel

- P-92** A SENESENCE-INFLAMMATORY SWITCH FROM CANCER-INHIBITORY TO CANCER-PROMOTING MECHANISM
Ela Elyada¹, Ariel Pribluda¹, Zoltan Wiener², Robert Goldstein¹, Ido burstain¹, Yael Morgenstern¹, Guy Brachya¹, Sharon Biton¹, Irit Alkalay¹, Moshe Oren³, Kari Alitalo², Eli Pikarsky^{1,4}, Yinon Ben-Neriah¹
¹*The Lautenberg Center for General and Tumor Immunology, The Institute of Medical Research, Hebrew University, Jerusalem, Israel*
²*Biomedicum Helsinki and the Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland*
³*Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel*
⁴*Department of Pathology, The Institute of Medical Research, Hebrew University-Hadassah Medical School, Jerusalem, Israel*
- P-93** CAN DNA REPLICATION DYNAMICS AND GENOMIC STABILITY BE AFFECTED BY INTRODUCING FRA16C-DERIVED AT-RICH SEQUENCE INTO ECTOPIC LOCI?
Michal Irony-Tur Sinai, Batsheva Kerem
Department of Genetics, The Life Sciences Institute, The Hebrew University, Jerusalem, Israel
- P-94** SERUM CEACAM1 AS A BIOMARKER FOR MONITORING OF MELANOMA PATIENTS
Rona Ortenberg^{1,2}, Sivan Sapoznik¹, Dov Zippel¹, Roni Shapira¹, Michal J. Besser^{1,2}, Jacob Schachter¹, Gal Markel^{1,2,3}
¹*Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel*
²*Clinical Microbiology and Immunology, Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel*
³*Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel*
- P-95** THE ROLE OF CEACAM1 IN METASTATIC MELANOMA AND THE DEVELOPMENT OF CEACAM1-TARGETED THERAPY
Rona Ortenberg^{1,2}, Sivan Sapoznik¹, Michal J. Besser^{1,2}, Liat Hershkoviz¹, Jacob Schachter¹, Gal Markel^{1,2,3}
¹*Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel*
²*Clinical Microbiology and Immunology, Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel*
³*Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel*
- P-96** NRN1: A NEW MELANOMA THERAPEUTIC TARGET?
Rona Ortenberg^{1,2}, Gilli Galore-Haskel^{1,2}, Raz Mutai², Jacob Schachter¹, Gal Markel^{1,2,3}
¹*Ella Institute of Melanoma, Sheba Medical Center, Ramat Gan, Israel*
²*Clinical Microbiology and Immunology, Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel*
³*Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel*
- P-97** CROSS TALK BETWEEN IL-1b and VEGF IS ESSENTIAL FOR TUMOR-MEDIATED ANGIOGENESIS
Elena Voronov¹, Yaron Carmi¹, Shahar Dotan¹, Malka R. White¹, Monica Huszar², Peleg Rider¹, Irena Kaplanov¹, Charles A. Dinarello³, Ron N. Apte¹
¹*The Shraga Segal Department of Immunology and Microbiology, Ben-Gurion University of the Negev, Beer-Sheva, Israel*
²*Pathology Department, Kaplan Medical Center, Rehovot, Israel*
³*Department of Medicine, University of Colorado, Denver, USA*
- P-98** THE EFFECTS OF IL-1 ON COLORECTAL CANCER DEVELOPMENT
Elena Voronov¹, Marina Bersudsky¹, Dmitry Fishman², Malka R. White¹, Nadya Ziv-Sokolovsky³, Charles A. Dinarello⁴, Ron N. Apte¹
¹*The Shraga Segal Department of Immunology and Microbiology, Ben Gurion University of the Negev, Beer Sheva, Israel*
²*Department of Morphology, Ben Gurion University of the Negev, Beer Sheva, Israel*
³*Department of Pathology, Kaplan Medical Center, Rehovot, Israel*
⁴*Department of Medicine, University of Colorado Denver, Colorado, USA*
- P-99** RATIONAL AND COMBINATORIAL ENGINEERING OF ANTAGONISTIC PROTEIN VARIANTS FOR CANCER IMAGING AND THERAPY
Niv Papo¹, Adam Silverman², Jennifer Lahti², Jennifer Cochran²
¹*Department of Biotechnology Engineering, Ben-Gurion University of the Negev, Beer-Sheva, Israel*
²*Department of Bioengineering, Stanford University, Palo Alto, USA*
- P-100** PIM-2-MEDIATED ACTIVATION OF THE DNA DAMAGE RESPONSE LEADS TO INCREASED VIABILITY FOLLOWING UV-RADIATION
Shahar Zirkin, Jeremy Don
The Mina & Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel
- P-101** HUMAN Vav1 EXPRESSION IN HEMATOPOIETIC AND CANCER CELL LINES IS REGULATED BY c-Myb AND BY CpG METHYLATION
Lena Ilan, Shulamit Katzav
Developmental Biology and Cancer Research, Hebrew University, Jerusalem, Israel

- P-102** THE ROLE OF hnRNP A2/B1 IN BREAST CANCER DEVELOPMENT AND TUMOR STAGE
Regina Golan-Gerstl¹, Ilana Lebenthal-Loinger¹, Ben Davidson², Reuven Reich³, Rotem Karni¹
¹*Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel*
²*Division of Pathology, Norwegian Radium Hospital, Rikshospitalet Medical Center, Oslo, Norway*
³*Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, The Hebrew University-Hadassah Medical School, Jerusalem, Israel*
- P-103** ALTERED GATA-3 FUNCTION IS ASSOCIATED WITH BREAST CANCER DEVELOPMENT AND PHENOTYPE
Helit Cohen, Rotem Ben-Hamo, Sol Efroni
The Mina & Everard Goodman Faculty of Life Science, Bar-Ilan University, Ramat-Gan, Israel
- P-104** Vav1: THE ONCOGENIC SWITCH
Shulamit Sebban Sebban, Marganit Farago, Dan Gashai, Lea Tzadik, Shulamit Katzav
Developmental Biology and Cancer Research, IMRIC, Hebrew University-Hadassah Medical School, Jerusalem, Israel
- P-105** TNF- α JOINS FORCES WITH ESTROGEN AND EGF IN BREAST CANCER MICROENVIRONMENT, LEADING TO METASTASIS FORMATION BY POTENTIATING ADHESIVE AND MIGRATORY PROPERTIES
Polina Weitzenfeld¹, Eline Von Konigslow¹, David Naor², Eva Turley³, Adit Ben-Baruch¹
¹*Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel*
²*The Lautenberg Center for General and Tumor Immunology, The Hebrew University - Hadassah Medical School, Jerusalem, Israel*
³*Departments of Oncology and Chemistry, London Regional Cancer Program, University of Western Ontario and London Health Sciences Center, London, Canada*
- P-106** DIFFERENTIAL EXPRESSION AND FUNCTIONS OF miRNAs IN GLIOMA STEM CELLS (GSCS) AND HUMAN NEURAL STEM CELLS (NSCS)
Ariel Bier¹, Michal Yalon^{2,3}, Elad Jacoby^{2,3}, Jasmine Jacob-Hirsch^{2,3}, Simona Cazacu⁴, Susan Finniss⁴, Cunli Xian⁴, Hae Kyung Lee⁴, Tom Mikkelsen⁴, Amos Toren^{2,3}, Chaya Brodie^{1,4}
¹*Everard and Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel*
²*Pediatric Hemato-Oncology, The Edmond and Lilly Safra Children's Hospital, The Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel*
³*The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel*
⁴*Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA*
- P-107** INTRACELLULAR GLYCOSAMINOGLYCANS AND CHEMOKINE DOMAINS REGULATE THE SECRETION OF THE PRO-MALIGNANCY CHEMOKINE CCL2 BY BREAST TUMOR CELLS
Ya'eli Lebel-Haziv¹, Gali Soria¹, Tsipi Meshel¹, Marcelo Ehrlich¹, Adva Yehekel², Elad Mamon¹, Adit Ben-Baruch¹
¹*Dept. Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel*
²*Bioinformatics Unit, Tel Aviv University, Tel Aviv, Israel*
- P-108** PREDICTION OF RESPONSE TO ADOPTIVE IMMUNOTHERAPY IN ADVANCED MELANOMA PATIENTS
Daphna Levy, Orit Itzhaki, Adva Kobi, Dragoslav Dzikich, Yaara Ohyiun, Noa Shoshani, Ronnie Shapira, Jacob Schachter, Michal Besser
Cancer Research Center, Sheba Medical Center, Tel Hashomer, Israel
- P-109** NICOTINAMIDE INHIBITS "VASCULOGENIC MIMICRY", AN ALTERNATIVE VASCULARIZATION PATHWAY OBSERVED IN HIGHLY AGGRESSIVE MELANOMA
Orit Itzhaki¹, Eyal Greenberg^{1,2}, Adva Kubi¹, Avraham Treves¹, Ronnie Shapira¹, Bruria Shalmon^{1,4}, Jacob Schachter¹, Michal Besser^{1,2}, Gal Markel^{1,2,3}
¹*Ella Institute of Melanoma, Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel*
²*Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel*
³*Talpiot Medical Leadership Program, Sheba Medical Center, Ramat-Gan, Israel*
⁴*Department of Pathology, Sheba Medical Center, Ramat Gan, Israel*
- P-110** ONCOGENE-INDUCED SENESCENCE DEPENDS ON LOW CELLULAR NUCLEOTIDE POOL
Assaf Bester, Dan Sarni, Batsheva Kerem
Department of Genetics, The Life Sciences Institute, Edmond J. Safra Campus, The Hebrew University, Jerusalem, Israel
- P-111** ESCIN ALONE AND IN COMBINATION WITH CHEMOTHERAPY DECREASES PANCREATIC CANCER CELL SURVIVAL
Adam Rimmon, Akiva Vexler, Liron Berkovich, Gideon Earon, Ilan Ron, Shahar Lev-Ari
Oncology Department, Tel Aviv Medical Center, Tel-Aviv, Israel

- P-112 THE ROLE OF hnRNP A1/A2 PROTEINS IN HEPATOCELLULAR CARCINOMA DEVELOPMENT AND PROGRESSION**
Asaf Shilo¹, Ilan Stein², Eli Pikarsky², Lars Zender³, Rotem Karni¹
¹*Department of Biochemistry and Molecular Biology, Hebrew University-Hadassah Medical School, Jerusalem, Israel*
²*Department of Immunology and Cancer Research, Hebrew University-Hadassah Medical School, Jerusalem, Israel*
³*Dept. of Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany*
- P-113 THE MOLECULAR MECHANISM OF MET-INDUCED PATH FINDING- AMOEBOID CELL MOTILITY TOWARDS METASTASIS**
Tammy Diamant-Levi, Adi Laser, Dganit Shkedy, Gidi Stein, Judith Horev, Ilan Tsarfaty
Department of Microbiology and Clinical Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- P-114 SELECTIVE IMPACT OF THE HISTONE DEACETYLASE INHIBITORS ON TUMOR AND NORMAL CELLS**
Nataly Tarasenko¹, Gabriela Rozic¹, Pnina Boer¹, Aida Inbal¹, Abraham Nudelman², Ada Rephaeli¹
¹*Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Petach-Tikva, Israel*
²*Chemistry Department, Bar-Ilan University, Ramat-Gan, Israel*
- P-115 DIFFERENTIAL REGULATION OF TRANSFORMING GROWTH FACTOR β (TGF- β) SIGNALING UPON MITOTIC ARREST OF OVARIAN CANCER CELLS**
Tal Hirschhorn¹, Lior Barzily¹, Nechama I. Smorodinsky^{1,2}, Marcelo Ehrlich¹
¹*Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel*
²*The Alec and Myra Marmot Hybridoma Unit, Tel Aviv University, Tel Aviv, Israel*
- P-116 IDENTIFICATION OF MELANOMA-REACTIVE T CELLS BASED ON ACQUISITION OF TUMOR ANTIGEN**
Galit Eisenberg¹, Arthur Machlenkin¹, Shoshana Frankenburg¹, Ronny Uzana¹, Soldano Ferrone², Eitan Yefenof³, Tamar Peretz¹, Michal Lotem¹
¹*Department of Oncology, Hadassah Medical Organization, Jerusalem, Israel*
²*Cancer Institute, University of Pittsburgh Cancer Institute, Pittsburgh, USA*
³*Lautenberg Center for General and Tumor Immunology, Hebrew University of Jerusalem, Jerusalem, Israel*
- P-117 MOLECULAR MECHANISMS OF CHEMOTHERAPY INDUCED SENESENCE IN HUMAN LUNG CANCER**
Reut Yosef-Hemo, Valery Krizhanovsky
Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
- P-118 SYSTEM BIOLOGY APPROACHES FOR PREDICTING AND CONTROLLING THE ANTI-TUMOR REACTIVITY OF TUMOR INFILTRATING LYMPHOCYTES**
Moran Hod¹, Kfir Oved¹, Michal Besser², Yoram Reiter¹
¹*Department of Biology, Technion-Israel Institute of Technology, Haifa, Israel*
²*Ella Institute for Melanoma Research, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel*
- P-119 BREAST CANCER INFLAMMATORY CYTOKINES MAKE NON-TRANSFORMED CELLS POTENTIAL CANDIDATES FOR RE-SEEDING AT THE PRIMARY TUMOR SITE**
Tal Leibovich-Rivkin, Tzipi Meshel, Adit Ben-Baruch
Dept. of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel
- P-120 REGULATION OF PRO-MALIGNANCY TRAITS IN MESENCHYMAL STEM CELLS RECRUITED TO BREAST TUMORS**
Shalom Lerrer, Christina Katanov, Adit Ben-Baruch
Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv, Israel
- P-121 STRUCTURE-FUNCTION STUDY OF THE SPLICING FACTOR SRSF1 IN CELLULAR TRANSFORMATION**
Ariel Shimoni-Sebag¹, Lars Zender², Rotem Karni¹
¹*Department of Biochemistry and Molecular Biology, The Hebrew University of Jerusalem, Jerusalem, Israel*
²*Department of Gastroenterology, Hepatology and Endocrinology Hannover Medical High School, Hannover, Germany*
- P-122 MEIG1 KO MICE ARE PREDISPOSED TO TUMOR DEVELOPMENT**
Revital Yaverboim, Tali Eldar, Jeremy Don
The Mina & Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel

- P-123** ONCOPATHWAY ADDICTION AS MASTER REGULATOR OF CANCER PROGRESSION/h1
Sol Efroni, Shay Shilo
The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel
- P-124** INCREASED INFLAMMATION AND ANGIOGENESIS IN PPM1A KO MICE
Zeev Dvashi¹, Hadas Jacobi¹, Maytal Shohat¹, Daniella Ben-Meir¹, Ruth Ashery-Padan², Shiran Ferber⁴, Mordechai Rosner³, Ronit Satchi-Fainaro⁴, Arie S. Solomon³, Sara Lavi¹
¹*Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences Tel Aviv University, Tel Aviv, Israel*
²*Human Genetics, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
³*Goldschleger Eye Research Institute, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel*
⁴*Physiology-Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel*
- P-125** Mimp/Mtch2 A MITOCHONDRIAL CARRIER HOMOLOG THAT PLAYS AN IMPORTANT ROLE IN TUMORIGENICITY AND OBESITY
Yamit Bar-Lev, Orly Cohen-Neeman, Raya Leibowitz-Amit, Gideon Stein, Gil Yerushalmi, Sharon Moshitch-Moshkovitz, Ilan Tsarfaty
Department of Clinical Immunology and Microbiology, Tel-Aviv University, Tel-Aviv, Israel
- P-126** A POTENTIAL FUNCTIONAL INTERACTION BETWEEN THE HUMAN GLIOMA TUMOR SUPPRESSOR CANDIDATE REGION 2 (GLTSCR2) GENE PRODUCT AND TP53
Avi-ad Buskila, Ronit Sarid
The Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel
- P-127** THE ROLE OF EFFUSION-DERIVED EXOSOMES FROM OVARIAN CARCINOMA PATIENTS IN MALIGNANT PROGRESSION
Olga Vaksman¹, Ben Davidson², Claes G. Trope², Reuven Reich¹
¹*Institute of Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel*
²*Division of Pathology, Department of Gynecology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway*
- P-128** CYP2D6 GENOTYPING FOR TAMOXIFEN ADMINISTRATION
Flavio Lejbkowitz, Ilana Cohen, Gad Rennert
Department of Community Medicine and Epidemiology, CHS National Cancer Control Center and Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel
- P-129** DETECTION OF UGT1A1*28 GENOTYPE IN CRC PATIENTS
Flavio Lejbkowitz, Ilana Cohen, Katerina Shulman, Gad Rennert
Department of Community Medicine and Epidemiology, CHS National Cancer Control Center and Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel
- P-130** TARGETING EGFR POSITIVE CANCER CELLS WITH CETUXIMAB-ZZ-PE38: RESULTS OF *IN VITRO* AND *IN VIVO* STUDIES
Rahamim Ben-Yosef¹, Itay Barnea¹, Victoria Karaush¹, Itai Benhar², Akiva Vexler¹
¹*Oncology, Tel-Aviv Medical Center, Tel-Aviv, Israel*
²*Microbiology and Biotechnology Department, Tel-Aviv University, Tel-Aviv, Israel*
- P-131** A NETWORK BIOLOGY APPROACH TO DECIPHER MELANOMA PATHWAYS
Yossi Kuttner, **Esti Yeager-Lotem**
Clinical Biochemistry, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- P-132** LIPID RAFTS COUPLE STORE-OPERATED Ca²⁺-ENTRY TO CONSTITUTIVE ACTIVATION OF PKB/Akt IN A Ca²⁺/calmodulin-, Src- AND PP2A-MEDIATED PATHWAY, AND PROMOTE MELANOMA TUMOR GROWTH
Shlomit Fedida-Metula¹, Ben Feldman¹, Ulianna Levin-Gromiko¹, Valeria Koshelev¹, Elena Voronov², **Daniel Fishman**¹
¹*Morphology, Ben-Gurion University of the Negev, Beer-Sheva, Israel*
²*The Shraga Segal Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beer-Sheva, Israel*
- P-133** SIGNIFICANT ANTICANCER EFFECT OF NOVEL 9-ANILINOACRIDINES ON MOST EPITHELIAL ORIGIN CANCERS: MECHANISM OF ACTION
Stella Aronov¹, Tzipi Beker¹, Maria Bogdanskyy¹, Amilia Meir¹, Katia Karakov¹, Garry Gellerman²
¹*Molecular Biology Department, Ariel University Center of Samaria, Ariel, Israel*
²*Biological Chemistry Department, Ariel University Center of Samaria, Ariel, Israel*

- P-134** AUTOLOGOUS RENAL CELL CARCINOMA VACCINES – INITIAL REPORT
Hovav Nechushtan¹, Merav Darash-Yahana¹, Tamar Hamburger¹, Inna Ben-David¹, Anna Kuznetz¹, Yael Gelfand¹,
 Aviad Zick¹, Ofer Gofrit², Tamar Peretz¹, Michal Lotem¹
¹Sharett Institute of Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel
²Urology Department, Hadassah Hebrew University Hospital, Jerusalem, Israel
- P-135** PKC η IS A NOVEL PROGNOSTIC MARKER IN NON-SMALL CELL LUNG CANCER
Ella Krasnitsky¹, Yael Baumfeld², Janna Freedman³, Netta Sion-Vardi⁴, Samuel Ariad³, Victor Novack², Etta Livneh¹
¹The Shraga Segal Department of Microbiology and Immunology, Ben Gurion University of the Negev, Beer Sheva, Israel
²Department of Clinical Research, Soroka University Medical Center, Beer Sheva, Israel
³Department of Oncology, Soroka University Medical Center, Beer Sheva, Israel
⁴Department of Pathology, Soroka University Medical Center, Beer Sheva, Israel
- P-136** PKC ϵ IS A NEGATIVE REGULATOR OF AKT INHIBITING THE IGF-I INDUCED PROLIFERATION
Noa Rotem-Dai, Galit Shahaf, Gabriela Koifman, Hadas Raveh-Amit, Sigal Adriana Frost, Etta Livneh
 The Shraga Segal department of Microbiology and Immunology, Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva, Israel
- P-137** DIMERIZATION OF NKp46 RECEPTOR IS ESSENTIAL FOR NKp46-MEDIATED LYSIS: CHARACTERIZATION OF THE DIMERIZATION SITE BY EPITOPE MAPPING
Rami Yossef¹, Michal Mendelson¹, Appel Michael Y¹, Alon Zilka¹, Uzi Hadad¹, Fabian Afergan¹, Benyamin Rosental¹, Stanislav Engel², Alex Braiman¹, Angel Porgador¹
¹Shraga Segal Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
²The Department of Clinical Biochemistry, and the National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel